Cxbladder

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial bladder cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help clinicians prioritize their time and clinical resources, optimize practice workﬂow, and improve the overall patient experience.

The Cxbladder suite:

Enables reliable risk stratification and rule out, to reduce the number of unnecessary cystoscopies and spare low risk patients the discomfort, anxiety and risks of an invasive procedure, while prioritizing those who require immediate care.
Helps clinicians confirm a diagnosis when other tests and procedures yield ambiguous results, reducing the likelihood of a missed tumor.
Offers a non-invasive surveillance alternative that can reduce the burden of cystoscopy, improving patient comfort and compliance.

Cxbladder works at a molecular level, analyzing five biomarker genes to rule out disease.

Accurate: Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results. The test works at a molecular level, analyzing biomarker genes to help rule out urothelial cancer.
Clinically proven: Proven performance in over 25 peer-reviewed publications for hematuria evaluation and surveillance. Cxbladder has been used by over 5,000 US urologists in more than 100,000 patients. In New Zealand the test is available to 75% of the population via public healthcare, and to all other residents through an e-commerce portal.
Non-invasive and easy-to-use: Cxbladder's non-invasive urine sampling system, with the option of in-home sample collection, is easy for both clinical teams and patients to use.

Hematuria Evaluation

Cxbladder Triage

Cxbladder Triage is a frontline diagnostic. The test is optimized to help de-intensify clinical work-up in hematuria patients with a low probability of urothelial bladder cancer, reducing the need for referral and invasive procedures, while prioritizing those who require further investigation.

Triage supports a new model for clinical practice and resource utilisation. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.

Cxbladder Detect

Cxbladder Detect is designed to improve practice workflow and efficiency in secondary urological care while giving patients the best experience possible. The test is optimized for the risk stratification of patients presenting with hematuria and helps to de-intensify clinical work-up in in those with a low probability of urothelial bladder cancer.

In cases of diagnostic ambiguity - atypical cytology and equivocal cystoscopy - Cxbladder Detect helps to resolve uncertainty, reducing the likelihood of a missed tumor.

Cxbladder Triage Plus

Designed as a single diagnostic for hematuria evaluation, Cxbladder Triage Plus is a next generation Cxbladder test that combines an analysis of 5 core mRNA biomarkers with DNA markers to deliver significant performance improvements over our existing tests.

The commercial launch of Cxbladder Triage Plus is expected soon.

Bladder Cancer Surveillance

Cxbladder Monitor

Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in patients being monitored for recurrent non-muscle bladder cancer. In suitable cases Monitor can alternate with cystoscopy to de-intensify surveillance. The test can replace cystoscopy in patients with no recurrence long term after shared decision between doctor and patient.

With the option of in-home sampling, Monitor improves patient comfort and compliance with cancer surveillance and management regimes.

Cxbladder is available in the following countries

The Americas

United States
Argentina
Uruguay
Venezuela

Asia Pacific

Australia
New Zealand
Singapore
Hong Kong
Taiwan
Thailand
Vietnam
Philippines
Malaysia
Indonesia
Brunei

Europe & the Middle East

Israel